Reply to van Wering et al

TO THE EDITOR
van Wering et al have used their extensive experience in immunophenotypic analysis of follow-up bone marrow samples from children with ALL to raise two issues discussed in our recent manuscript describing multifluorescent TCRG VG and JG typing at diagnosis: 1 first, the percentage of T lymphocytes present in complete remission bone marrow aspirates at the end of induction therapy and second, the capacity of fluorescent gene scan analysis without junction specific probes to reproducibly achieve a 5 × 10 −3 level of sensitivity of detection.
With regard to the proportion of T lymphocytes in early complete remission bone marrow, this is obviously determined by the extent of dilution by peripheral blood, which is, in turn, determined by the volume of marrow aspirated. While we accept that hemodilution is more likely in early remission samples, we are surprised at the mean 38% CD3 positivity described by van Wering, albeit analyzed on a gated population. Morphological assessment of approximately day 35 bone marrow samples from 32 children treated on the French FRALLE93 protocol showed a median lymphocyte count of 9.5%, mean 14%, range 0-67%. This difference is unlikely to be protocolbased since both are BFM-based, and is more likely to result from the different analytical procedures and/or the extent of hemodilution. As a measure of the latter, we have compared the proportion of erythroblasts and lymphocytes. Morphologically, erythroid cells represented on average 42% (median 37%; range 3-72% ) of nucleated cells, in keeping with relatively limited hemodilution. It would be interesting to compare these data with the immunophenotypic estimate of the proportion of erythroid precursors in the Ficolled fractions analyzed by van Wering et al.
We are well aware that the presence of polyclonal T lymphocytes reduces the sensitivity of detection of a clonal population, 2 but do not agree that the strategies described in Delabesse et al 1 cannot reproducibly achieve a sensitivity of 5 × 10 −3 in early remission marrow. Direct comparison of a diagnostic ALL TCRG Vfi-JP1/2 rearrangement diluted in parallel into a 10% PBL/90% myeloid DNA mix, into the patients own day 35 bone marrow and into a day 35 marrow from another individual showed a level of detection below 5 × 10 −3 in all three situations, albeit with improved sensitivity in the 10% PBL mix. Furthermore, it should be emphasized that the data presented in Delabesse et al was primarily intended as a comparative analysis of the use of consensus vs VG-specific primers in multiplex vs monoplex PCR strategies. As stated in the manuscript, 'the VG-JG-specific fluorescent PCR analyses were not optimised to maximise specificity, being used under multiplex conditions. It is therefore possible that their potential sensitivity is higher'. In keeping with this, since optimising monoplex fluorescent genescan analysis in collaboration with H Cavé (H Guidal, H Cavé et al, manuscript submitted), we have analyzed day 27-63 bone marrows from 28 ALLs, including 19 children. Diagnostic blasts are evaluated after Ficol-Hypaque separation and their sensitivity of detection evaluated after dilution into either the patients . Not surprisingly, all five alleles demonstrating insufficient sensitivity at 5 × 10 −3 or more belong to the predominant VGfI, when competition with polyclonal rearrangements is maximal. We are aware that these strategies will not be appropriate for the identification of patients at a potentially extremely low risk of relapse, as identified by van Dongen et al. 3 We do, however, consider that, with appropriate precautions to determine sensitivity of individual rearrangements, the simplified strategies which we have described represent a valid alternative to junction specific strategies for the prospective detection at remission induction of patients at a high risk of relapse, in whom a cut-off of 10 −2 has been shown to suffice. 4 Only prospective incorporation of different molecular follow-up strategies into current protocols will determine which are best adapted to therapeutic stratification based on individual patient risk. 
